Login
Home
Charts
Search
Watchlist
Products

Black Rose Industries Ltd

BLACKROSE·BSE
114.00+0.26%Wed, 23 Sept '26 15:52

Black Rose Industries Ltd

BLACKROSE
BSE
114.00
+0.26%
|Wed, 23 Sept '26 15:52
SOICxStockScans Reports
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
581Cr
Close
Close Price
114.00
Industry
Industry
Speciality Chemicals
PE
Price To Earnings
20.28
PS
Price To Sales
1.65
Revenue
Revenue
352Cr
Rev Gr TTM
Revenue Growth TTM
8.89%
PAT Gr TTM
PAT Growth TTM
40.27%

Quarterly Results

Consolidated
Standalone
Numbers
Percentage
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
84941159893888360847510489
Growth YoY
Revenue Growth YoY%
-17.7-4.03.812.211.0-6.3-28.1-39.1-9.8-14.325.548.8
Expenses
ExpensesCr
7686108928680745477699175
Operating Profit
Operating ProfitCr
87767896771314
OPM
OPM%
9.57.86.26.37.19.210.39.88.68.712.516.1
Other Income
Other IncomeCr
112111010111
Interest Expense
Interest ExpenseCr
000000001000
Depreciation
DepreciationCr
111111111111
PBT
PBTCr
87866886661214
Tax
TaxCr
222222222234
PAT
PATCr
6565566444910
Growth YoY
PAT Growth YoY%
289.71,914.8214.916.5-22.04.81.9-11.2-5.9-22.862.0148.0
NPM
NPM%
7.25.84.94.85.16.57.07.05.35.89.011.7
EPS
EPS
1.21.11.10.90.91.11.10.80.90.91.92.0
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
84941159893888360847510489
Growth YoY
Revenue Growth YoY%
-17.7-4.03.812.211.0-6.3-28.1-39.1-9.8-14.325.548.8
Expenses
ExpensesCr
7686108928680745477699175
Operating Profit
Operating ProfitCr
87767896771314
OPM
OPM%
9.57.86.26.37.19.210.39.88.68.712.516.1
Other Income
Other IncomeCr
112111010111
Interest Expense
Interest ExpenseCr
000000001000
Depreciation
DepreciationCr
111111111111
PBT
PBTCr
87866886661214
Tax
TaxCr
222222222234
PAT
PATCr
6565566444910
Growth YoY
PAT Growth YoY%
289.71,914.8214.916.5-22.04.81.9-11.2-5.9-22.862.0148.0
NPM
NPM%
7.25.84.94.85.16.57.07.05.35.89.011.7
EPS
EPS
1.21.11.10.90.91.11.10.80.90.91.92.0

Profit & Loss

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
177242298309373380488430380337323352
Growth
Revenue Growth%
-9.636.423.23.720.71.928.5-11.8-11.6-11.3-4.38.9
Expenses
ExpensesCr
168227276285340340442417352308290311
Operating Profit
Operating ProfitCr
91422243340451428293341
OPM
OPM%
5.26.07.37.78.710.59.33.27.48.710.111.7
Other Income
Other IncomeCr
111101125333
Interest Expense
Interest ExpenseCr
454331121112
Depreciation
DepreciationCr
332223333344
PBT
PBTCr
2816192737431129283038
Tax
TaxCr
13457911377810
PAT
PATCr
251214212732821212329
Growth
PAT Growth%
203.8212.3134.118.248.932.816.2-75.2168.1-1.37.340.3
NPM
NPM%
0.92.14.04.55.57.26.51.85.66.27.08.1
EPS
EPS
0.30.92.32.74.05.46.31.64.24.14.45.6
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
177242298309373380488430380337323352
Growth
Revenue Growth%
-9.636.423.23.720.71.928.5-11.8-11.6-11.3-4.38.9
Expenses
ExpensesCr
168227276285340340442417352308290311
Operating Profit
Operating ProfitCr
91422243340451428293341
OPM
OPM%
5.26.07.37.78.710.59.33.27.48.710.111.7
Other Income
Other IncomeCr
111101125333
Interest Expense
Interest ExpenseCr
454331121112
Depreciation
DepreciationCr
332223333344
PBT
PBTCr
2816192737431129283038
Tax
TaxCr
13457911377810
PAT
PATCr
251214212732821212329
Growth
PAT Growth%
203.8212.3134.118.248.932.816.2-75.2168.1-1.37.340.3
NPM
NPM%
0.92.14.04.55.57.26.51.85.66.27.08.1
EPS
EPS
0.30.92.32.74.05.46.31.64.24.14.45.6

Balance Sheet

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
55555555555
Reserves
ReservesCr
162030436288117122140148164
Current Liabilities
Current LiabilitiesCr
4160514665474628415533
Non Current Liabilities
Non Current LiabilitiesCr
222418159787766
Total Liabilities
Total LiabilitiesCr
84109105109141147176162193214208
Current Assets
Current AssetsCr
44706976102104130112142164153
Non Current Assets
Non Current AssetsCr
4039373339434650505055
Total Assets
Total AssetsCr
84109105109141147176162193214208
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
55555555555
Reserves
ReservesCr
162030436288117122140148164
Current Liabilities
Current LiabilitiesCr
4160514665474628415533
Non Current Liabilities
Non Current LiabilitiesCr
222418159787766
Total Liabilities
Total LiabilitiesCr
84109105109141147176162193214208
Current Assets
Current AssetsCr
44706976102104130112142164153
Non Current Assets
Non Current AssetsCr
4039373339434650505055
Total Assets
Total AssetsCr
84109105109141147176162193214208

Cash Flow

Consolidated
Standalone
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
6712111710152317-1345
Investing Cash Flow
Investing Cash FlowCr
0000-7-5-6-12-1012-26
Financing Cash Flow
Financing Cash FlowCr
-6-4-11-9-9-5-4-11-5-8-18
Net Cash Flow
Net Cash FlowCr
021220502-91
Free Cash Flow
Free Cash FlowCr
5611101011151714-1638
CFO To PAT
CFO To PAT%
353.8135.199.280.684.137.746.7286.479.2-59.7200.6
CFO To EBITDA
CFO To EBITDA%
62.047.253.346.953.425.932.8163.060.0-42.6138.4
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
6712111710152317-1345
Investing Cash Flow
Investing Cash FlowCr
0000-7-5-6-12-1012-26
Financing Cash Flow
Financing Cash FlowCr
-6-4-11-9-9-5-4-11-5-8-18
Net Cash Flow
Net Cash FlowCr
021220502-91
Free Cash Flow
Free Cash FlowCr
5611101011151714-1638
CFO To PAT
CFO To PAT%
353.8135.199.280.684.137.746.7286.479.2-59.7200.6
CFO To EBITDA
CFO To EBITDA%
62.047.253.346.953.425.932.8163.060.0-42.6138.4

Ratios

Consolidated
Standalone
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
77135229233388887998542624456325581
Price To Earnings
Price To Earnings
46.926.919.516.818.832.331.368.529.421.714.520.3
Price To Sales
Price To Sales
0.40.60.80.81.02.32.01.31.61.41.01.6
Price To Book
Price To Book
3.75.36.54.85.89.58.24.34.33.01.93.4
EV To EBITDA
EV To EBITDA
12.511.911.710.612.322.522.037.921.715.69.713.5
Profitability Ratios
Profitability Ratios
GPM
GPM%
11.511.211.912.013.215.514.310.114.818.119.319.3
OPM
OPM%
5.26.07.37.78.710.59.33.27.48.710.111.7
NPM
NPM%
0.92.14.04.55.57.26.51.85.66.27.08.1
ROCE
ROCE%
11.719.129.830.334.034.632.29.819.917.918.518.5
ROE
ROE%
7.719.733.128.730.629.526.16.214.613.713.313.3
ROA
ROA%
1.94.611.212.714.618.718.14.911.09.810.810.8
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
77135229233388887998542624456325581
Price To Earnings
Price To Earnings
46.926.919.516.818.832.331.368.529.421.714.520.3
Price To Sales
Price To Sales
0.40.60.80.81.02.32.01.31.61.41.01.6
Price To Book
Price To Book
3.75.36.54.85.89.58.24.34.33.01.93.4
EV To EBITDA
EV To EBITDA
12.511.911.710.612.322.522.037.921.715.69.713.5
Profitability Ratios
Profitability Ratios
GPM
GPM%
11.511.211.912.013.215.514.310.114.818.119.319.3
OPM
OPM%
5.26.07.37.78.710.59.33.27.48.710.111.7
NPM
NPM%
0.92.14.04.55.57.26.51.85.66.27.08.1
ROCE
ROCE%
11.719.129.830.334.034.632.29.819.917.918.518.5
ROE
ROE%
7.719.733.128.730.629.526.16.214.613.713.313.3
ROA
ROA%
1.94.611.212.714.618.718.14.911.09.810.810.8
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
- **lead** - Black Rose Industries began as a chemical matchmaker three decades ago, connecting Indian factories with specialty molecules from Japan and Germany, and then did something its suppliers rarely do: it asked for the recipe, built the plant, and became the first company in South Asia to make a critical industrial building block from scratch. That pattern - use distribution cash flows and relationships to fund manufacturing in a niche where India is import-dependent, then dominate it - is the recurring logic of the business. # Business segments Two engines that feed each other - a distribution arm that is the revenue backbone and market-intelligence nerve centre, and a manufacturing arm that turns that intelligence into import-substitution factories with global cost advantages. ## 1. Chemical distribution: the legacy engine that funds and informs everything else **A stock-and-sale merchant that imports specialty chemicals from the world’s best manufacturers and sells them to hundreds of Indian factories, earning a spread while building the relationships that later become manufacturing opportunities.** - **The original business, still the biggest** - founded in 1990, distribution contributes roughly two-thirds of revenue and gives the company a ground-level view of what Indian industry is buying, from whom, and at what price. - **Direct partnerships, no middlemen** - the company is the exclusive Indian distribution partner for global chemical houses, especially from Japan, Germany, and Thailand, a rare arrangement since Japanese manufacturers typically route sales through Japanese trading firms. - **A broad basket with a concentrated core** - the portfolio spans products like resorcinol, ethanolamines, and acrylonitrile, but the top five products reliably generate over 70% of segment revenue and profit, serving industries from agrochemicals to tyre-making. - **Inventory as a service** - the company holds stock in rented warehouses across major consuming hubs like Bhiwandi, Morbi, and Vapi, so customers get uninterrupted supply even when global shipping snarls, which is why they prefer an organised distributor over a trader. - **Market leader in most of what it sells** - the company claims leadership in the majority of its distribution products, built on transparent, formula-based pricing that keeps customers loyal through price cycles. ## 2. Chemical manufacturing: where distribution relationships become factories **The company takes a product it used to import, licenses the best available technology, builds capacity at a fraction of the global cost, and then supplies both India and export markets from a single zero-liquid-discharge site in Gujarat.** - **Started with a phone call to a supplier** - in 2010, Mitsui Chemicals stopped making acrylamide solids; Black Rose, which had distributed the product, asked for the bio-catalytic technology license and built South Asia’s first acrylamide liquid plant by 2013, avoiding the cost of shipping a product that is half water. - **The acrylamide franchise is a cost-leadership story** - the plant runs on Mitsui’s enzyme-based process with low energy use and no by-products, and capacity was expanded to 32,000 tonnes per year (20,000 for merchant sale) at a capital cost so low it gave the company global cost leadership per installed tonne. - **The only acrylamide powder maker outside China** - using proprietary in-house technology, the company built a 3,600-tonne-per-year solid acrylamide plant for less than Rs. 5 crores, making it the sole non-Chinese producer and insulating Indian buyers from Chinese dumping and import duties of 7.5%. - **Downstream moves that lock in the chain** - it makes N-Methylol Acrylamide (NMA), where it is the only Indian merchant producer and holds a majority domestic share, and it is piloting polyacrylamide solid, a 100,000-tonne Indian market currently served almost entirely by imports. - **A new amine project with a familiar playbook** - the company is studying a 5,000-tonne specialty amines plant with Koei Chemical of Japan, where Black Rose will build and operate the facility using Koei’s technology, replicating the Mitsui model with a new partner. # Group structure and partners **A single listed entity controlled by a Mauritian holding company, with no debt, no joint ventures, and a deliberate strategy of converting Japanese technology partnerships into manufacturing monopolies.** - **Clean structure** - Black Rose Industries is a standalone Bombay Stock Exchange-listed company, 56.47% held by Wedgewood Holdings of Mauritius, with a recently closed Japanese subsidiary that had served its purpose of building supplier relationships. - **Mitsui Chemicals is the foundational partner** - the exclusive bio-catalytic technology license from Mitsui, granted in 2010, is the reason the acrylamide plant exists and remains the core manufacturing moat. - **Koei Chemical is the next bet** - the 2025 feasibility study for amine production follows the same template: Koei provides the know-how, Black Rose provides the plant and the Indian market access. - **Distribution principals are a portfolio of moats** - direct relationships with Sumitomo Chemical, LANXESS, Kuraray, and over a dozen other global manufacturers give the company exclusive access to products that Indian customers cannot easily source elsewhere.

Documents — Black Rose Industries Ltd

  • Q4 FY2026 Earnings Call Transcript (Mar 2026, PDF): https://www.stockscans.in/document/t1u7v0cvll1r7pkbrjva74bh.pdf
  • Q4 FY2025 Earnings Call Transcript (Mar 2025, PDF): https://www.stockscans.in/document/gyanxlsl1a3n8we83dmci39s.pdf
  • Q3 FY2025 Earnings Call Transcript (Dec 2024, PDF): https://www.stockscans.in/document/sqh4zjx30hhjenr6vjvphpue.pdf
  • Q1 FY2025 Earnings Call Transcript (Jun 2024, PDF): https://www.stockscans.in/document/ros1hdmt6g6asefb2ct6uf1j.pdf
  • Q4 FY2024 Earnings Call Transcript (Mar 2024, PDF): https://www.stockscans.in/document/0dleh28qtxj966whepmi59e8.pdf
  • Q3 FY2024 Earnings Call Transcript (Dec 2023, PDF): https://www.stockscans.in/document/cg42ot7ilzb262qeb58lv9yb.pdf
  • Q2 FY2024 Earnings Call Transcript (Sep 2023, PDF): https://www.stockscans.in/document/4f6xcose5efq9g6b6x50cp4u.pdf
  • Q1 FY2024 Earnings Call Transcript (Jun 2023, PDF): https://www.stockscans.in/document/0zr48jdno1ph5k0mqt6o44tw.pdf
  • Q1 FY2027 Quarterly Result (Jun 2026, PDF): https://www.stockscans.in/document/fuqk2kzxvitoee8315umtvzy.pdf
  • Q4 FY2026 Quarterly Result (Mar 2026, PDF): https://www.stockscans.in/document/yfoneprf27k663qikpxftosf.pdf
  • Q3 FY2026 Quarterly Result (Dec 2025, PDF): https://www.stockscans.in/document/jhxoxbsu77av91o02neo260z.pdf
  • Q2 FY2026 Quarterly Result (Sep 2025, PDF): https://www.stockscans.in/document/e2hknjx0npblgcecy59ii87w.pdf
  • Q1 FY2026 Quarterly Result (Jun 2025, PDF): https://www.stockscans.in/document/a0e0amwq2f6txqr7eglxnhy0.pdf
  • Q4 FY2025 Quarterly Result (Mar 2025, PDF): https://www.stockscans.in/document/txvwfzhn2ghehcgqqa4mwlcz.pdf
  • Q3 FY2025 Quarterly Result (Dec 2024, PDF): https://www.stockscans.in/document/vjcohskvcsvw70f6yma41vvh.pdf
  • Q2 FY2025 Quarterly Result (Sep 2024, PDF): https://www.stockscans.in/document/5behwc3ltjp3thgt16ilbces.pdf
  • Q4 FY2026 Investor Presentation (Mar 2026, PDF): https://www.stockscans.in/document/vox8yatkodz31q5m2jnva6ux.pdf
  • FY2026 Annual Report (PDF): https://www.stockscans.in/document/u60xovebmro5j0c85lgnpli8.pdf
  • FY2025 Annual Report (PDF): https://www.stockscans.in/document/5ruwsojpe2dyw0shpwlnktgh.pdf
  • FY2024 Annual Report (PDF): https://www.stockscans.in/document/auzy12co0j93v92h7ridkbse.pdf
  • FY2023 Annual Report (PDF): https://www.stockscans.in/document/aidsaqu1ksfbvwzjjl6sij7p.pdf
  • FY2022 Annual Report (PDF): https://www.stockscans.in/document/yi33cuuhr4hy8y5zsxdzm0j5.pdf
  • FY2021 Annual Report (PDF): https://www.stockscans.in/document/lm95kn37k8a1p6i3xaoflt2u.pdf
  • FY2020 Annual Report (PDF): https://www.stockscans.in/document/9x2tga09i61btjhljfvl76ln.pdf

Concall Transcript Summaries — Black Rose Industries Ltd

  • Q4 FY2026 Concall Transcript Summary (Mar 2026): https://www.stockscans.in/company/BSE%3ABLACKROSE/transcript-notes/202603/t1u7v0cvll1r7pkbrjva74bh.pdf
  • Q4 FY2025 Concall Transcript Summary (Mar 2025): https://www.stockscans.in/company/BSE%3ABLACKROSE/transcript-notes/202503/gyanxlsl1a3n8we83dmci39s.pdf
  • Q3 FY2025 Concall Transcript Summary (Dec 2024): https://www.stockscans.in/company/BSE%3ABLACKROSE/transcript-notes/202412/sqh4zjx30hhjenr6vjvphpue.pdf
  • Q1 FY2025 Concall Transcript Summary (Jun 2024): https://www.stockscans.in/company/BSE%3ABLACKROSE/transcript-notes/202406/ros1hdmt6g6asefb2ct6uf1j.pdf
  • Q4 FY2024 Concall Transcript Summary (Mar 2024): https://www.stockscans.in/company/BSE%3ABLACKROSE/transcript-notes/202403/0dleh28qtxj966whepmi59e8.pdf
  • Q3 FY2024 Concall Transcript Summary (Dec 2023): https://www.stockscans.in/company/BSE%3ABLACKROSE/transcript-notes/202312/cg42ot7ilzb262qeb58lv9yb.pdf
  • Q2 FY2024 Concall Transcript Summary (Sep 2023): https://www.stockscans.in/company/BSE%3ABLACKROSE/transcript-notes/202309/4f6xcose5efq9g6b6x50cp4u.pdf
  • Q1 FY2024 Concall Transcript Summary (Jun 2023): https://www.stockscans.in/company/BSE%3ABLACKROSE/transcript-notes/202306/0zr48jdno1ph5k0mqt6o44tw.pdf